Corporate Information
A Word from CEO
Management Team
Advisor & Collaborations
Company
A Word from CEO
SUSMED aims to achieve sustainable medicine.
Social security provides healthcare to anyone who needs it, and is essential if people are to live their lives with peace of mind.
However, in our aging society, the cost of medical care is increasing as medical care becomes more advanced, placing the entire social security system at risk.
Medicine and medical care are the infrastructure that supports society and are the source from which next-generation innovation springs.
By organically combining the needs of frontline medicine and medical research with IT technology we believe that we can optimize medical care for individuals and society as a whole in an uncompromising manner both now and in the future.
We also believe that by facilitating cooperation among medical professionals across a wide range of fields, we will be able to make possible better medical care, which can protect the social security system and enable people to play an active role and take on new challenges in society.
Management Team
Executive Directors
Taro Ueno
Representative Director
Taro Ueno
Yusuke Yajima
Director and COO
Yusuke Yajima
Tomomitsu Motohashi
Director and CTO
Tomomitsu Motohashi
Takayuki Kohara
Director (administration)
Takayuki Kohara
Outside Directors
Kuniaki Kaga
Kuniaki Kaga
Kuniaki Kaga
Yasuhiro Yamada
Statutory Auditors
Yoshiko Akishima
Yoshiko Akishima
Kenta Nagao
Kenta Nagao
Makiko Yamamoto
Makiko Yamamoto
Advisor & Collaborations
Advisor

Advanced Telecommunications Research Institute International(ATR)

ATR Brain Information Communication Research Laboratory Group.

Chief

Mitsuo Kawato
Mitsuo Kawato

Sosei Group Corporation

Chairman of the Board

Shinichi Tamura
Shinichi Tamura
Collaborations
Tohoku University
We are verifying how efficient our own clinical trial system, in which blockchain technology is implemented, makes clinical trial process (monitoring process etc.). By reducing the burden of operations, we will facilitate clinical trials at ARO (Academic Research Organization) and Clinical Research Core Hospitals.
Kyusyu University
We are developing data collecting platform for catheter ablation and analyzing the data to provide with treatment suggestions. This is adopted as "Practical Research Project for Life-Style related Diseases including Cardiovascular Diseases and Diabetes Mellitus" of AMED.
TMDU
We are developing efficient and highly-trusted monitoring methods in clinical trial process using blockchain technology.
NCNP
We are developing efficient and highly-trusted disease registry using blockchain technology.
Nagoya University
Kurume University
University of Zurich
National Cancer Center Hospital East
National Cancer Center Hospital
Japanese Foundation for Cancer Research
Nagoya City University
YOKOHAMA CITY UNIVERSITY
Company
Name
SUSMED, Inc.
Founding
February 23, 2016 (Founded as a limited liability company on July 31, 2015)
Address
MFPR Nihonbashi Honcho Bldg 10F,3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023
CEO
Taro UENO
Business
  • Development of smartphone-based therapeutic apps
  • Providing therapeutic app development platform
  • Development and providing of clinical trial systems with blockchain technology
  • Provision of medical data analysis and consulting services through statistical analysis and machine learning
Authorization / Registration
Manufacture of medical devices (Registration No.13BZ201591) Second-class marketing license for medical devices (Permission number 13B2X10494) Selling and Leasing Agent of Medical Devices
Access Map
MFPR Nihonbashi Honcho Bldg 10F, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo 103-0023
JR Sobu Main Line: 2-minute walk from Shin-Nihonbashi station
Tokyo Metro Hibiya Line: 2-minute walk from Kodenmacho station
Tokyo Metro Ginza Line: 7-minute walk from Mitsukoshimae station
History
July 2015
Established as a limited liability company.
October 2015
Adopted as NEDO-TCP Program.
February 2016
Changed to a joint-stock company.
March 2016
Adopted as NEDO-SUI Program.
September 2016
Commenced a clinical trial at two facilities in Japan using a smartphone app for treating insomnia.
December 2016
Increased capital by approximately JPY 70 million by allocation of new shares to Beyond Next Ventures, Inc.
April 2017
Adopted as NEDO-STS Program.
June 2018
Increased capital by approximately JPY 720 million by allocation of new shares to multiple companies.
November 2018
Adopted as NEDO-SCA Program.
July 2019
Selected as "J-Startup", supporting program for startups by METI, JETRO, NEDO.
July 2019
Adopted as NEDO-AI Program.
July 2020
Consecutively adopted as NEDO-AI Program.
December 2020
Increased capital by approximately JPY 1.5 billion by allocation of new shares to multiple companies.
December 2021
Listed on Tokyo Stock Exchange Mothers
December 2021
Entered into commercialization agreement with SHIONOGI about DTx for Insomnia
February 2022
Completed market authorization approval of DTx for Insomnia
March 2022
Invested into Collabo CREATE CO., LTD.
March 2022
Adopted a joint research with Kyushu Univ. as AMED program.
April 2022
Started a joint development of DTx for functional disorders with Nagoya City Univ.
May 2022
Adopted a joint research with National Center of Neurology and Psychiatry as AMED program.
June 2022
Entered into an agreement with Aculys Pharma, Inc. about the world’s first clinical trial utilizing blockchain technology.
June 2022
Started a joint research with Cancer Institute Hospital of JFCR about an actual status of irAEs.
September 2022
Started a joint research for causal discovery with Shiga Univ.
October 2022
Adopted a joint DTx development with Nagoya City Univ. as AMED program.
November 2022
Entered into an agreement with KYORIN Pharmaceutical Co., LTD. about co-development of DTx.
November 2022
Study protocol and results of DTx for Insomnia was published in SLEEP.